Skip to main content

Susan Kay Murphy, PhD

Murphy
Associate Professor in Obstetrics and Gynecology
Campus Mail: 701 W. Main Street, Suite 510, Room 5140, Durham, NC 27701
Phone: (919) 681-3423
Email: susan.murphy@duke.edu

My research interests are largely centered around epigenetics and the role of epigenetic modifications in health and disease. My research projects include studies of gynecologic malignancies, including working on approaches to target ovarian cancer cells that survive chemotherapy and later give rise to recurrent disease.  I have ongoing collaborative projects in which we investigate the nature of the Developmental Origins of Health and Disease (DOHaD) hypothesis. DOHaD reflects the idea that our early environment plays an important part in shaping our risk of developing neurodevelopmental disorders or other chronic health problems. I am currently focused on preconception exposures in males with studies of the impact of cannabis use on the sperm epigenome and heritability of these effects. My lab is also working on the effects of in utero exposures, with our primary work revolving around the Newborn Epigenetics STudy (NEST), a mother-infant dyad cohort recruited from central North Carolina between 2005 and 2011 and whom we have followed since early pregnancy.

Education and Training

  • Ph.D., Wake Forest University, 1998
  • B.A., University of North Carolina - Charlotte, 1992

Selected Grants and Awards

Publications

Lee, P. S., V. Teaberry, A. E. Bland, Z. Huang, A Alvarez Secord, A. Berchuck, and S. K. Murphy. “MAL, a gene associated with survival in epithelial ovarian cancer, is epigenetically regulated.” In Gynecologic Oncology, 108:S125–S125. ACADEMIC PRESS INC ELSEVIER SCIENCE, 2008.

Scholars@Duke

Matsumura, N., Z. Huang, T. Perry, D. Kroyer, T. Baba, S. Mori, S. Fujii, A. Berchuck, and S. K. Murphy. “Methylation in ovarian cancer is related to poor prognosis and suppression of the transforming growth factor signaling pathway.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S104–S104.

Scholars@Duke

Bernardini, M. Q., P. Lee, T. Baba, R. S. Whitaker, S. K. Murphy, and A. Berchuck. “Microarray analysis defines patterns of gene expression associated with mutation of TP53 in ovarian cancer.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S84–S84.

Scholars@Duke

Baba, T., S. Mori, N. Matsumura, M. Bernardini, S. Fujii, A. Berchuck, and S. K. Murphy. “Microarray analysis identifies NSC668814 as a potentially active chemotherapeutic agent for platinum-resistant ovarian cancers with TP53 mutations.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S72–S72.

Scholars@Duke

Baba, T., P. A. Convery, N. Matsumura, R. S. Whitaker, T. Perry, Z. Huang, S. Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Gynecologic Oncology, 108:S104–S104, 2008.

Scholars@Duke

Kondoh, E., T. Baba, N. Matsumura, S. Fujii, A. Berchuck, and S. K. Murphy. “Targeting dormant ovarian cancer cells.” Gynecologic Oncology 108, no. 3 (March 1, 2008): S13–14.

Scholars@Duke

Baba, Tsukasa, Patricia Convey, Noriomi Matsumura, Regina S. Whitaker, Tiffany Perry, Zhiqing Huang, Seiichi Mori, et al. “Stem cell marker CD133 (PROMININ-1) is epigenetically regulated in ovarian cancer.” In Cancer Biomarkers, 4:175–76, 2008.

Scholars@Duke

O’Sullivan, Fiona M., Susan K. Murphy, Lauren R. Simel, Amanda McCann, John J. Callanan, and Catherine M. Nolan. “Imprinted expression of the canine IGF2R, in the absence of an anti-sense transcript or promoter methylation.” Evol Dev 9, no. 6 (November 2007): 579–89. https://doi.org/10.1111/j.1525-142X.2007.00198.x.

Full Text

Baba, Tsukasa, Seiichi Mori, Noriomi Matsumura, Masatoshi Kariya, Susan K. Murphy, Eiji Kondoh, Takashi Kusakari, et al. “Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.” Biochem Biophys Res Commun 360, no. 2 (August 24, 2007): 363–69. https://doi.org/10.1016/j.bbrc.2007.06.070.

Full Text

Hempel, Nadine, Tam How, Mei Dong, Susan K. Murphy, Timothy A. Fields, and Gerard C. Blobe. “Loss of betaglycan expression in ovarian cancer: role in motility and invasion.” Cancer Res 67, no. 11 (June 1, 2007): 5231–38. https://doi.org/10.1158/0008-5472.CAN-07-0035.

Full Text

Pages